BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22250051)

  • 21. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
    Zhou XP; Gimm O; Hampel H; Niemann T; Walker MJ; Eng C
    Am J Pathol; 2000 Oct; 157(4):1123-8. PubMed ID: 11021816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.
    Xie H; Rachakonda PS; Heidenreich B; Nagore E; Sucker A; Hemminki K; Schadendorf D; Kumar R
    Oncotarget; 2016 Mar; 7(13):16490-504. PubMed ID: 26909863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma.
    Wagner SN; Wagner C; Briedigkeit L; Goos M
    Br J Dermatol; 1998 Jan; 138(1):13-21. PubMed ID: 9536218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrative genome comparison of primary and metastatic melanomas.
    Kabbarah O; Nogueira C; Feng B; Nazarian RM; Bosenberg M; Wu M; Scott KL; Kwong LN; Xiao Y; Cordon-Cardo C; Granter SR; Ramaswamy S; Golub T; Duncan LM; Wagner SN; Brennan C; Chin L
    PLoS One; 2010 May; 5(5):e10770. PubMed ID: 20520718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.
    Horn S; Leonardelli S; Sucker A; Schadendorf D; Griewank KG; Paschen A
    J Natl Cancer Inst; 2018 Jun; 110(6):677-681. PubMed ID: 29917141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GAB2 amplifications refine molecular classification of melanoma.
    Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
    Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic alterations in main candidate genes during melanoma progression.
    Sini MC; Doneddu V; Paliogiannis P; Casula M; Colombino M; Manca A; Botti G; Ascierto PA; Lissia A; Cossu A; Palmieri G
    Oncotarget; 2018 Feb; 9(9):8531-8541. PubMed ID: 29492214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
    Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin.
    Poetsch M; Dittberner T; Cowell JK; Woenckhaus C
    Oncogene; 2000 Nov; 19(50):5817-20. PubMed ID: 11126369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
    Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
    Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
    Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
    Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
    Soto JL; Cabrera CM; Serrano S; López-Nevot MA
    BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas.
    Weaver-Feldhaus J; Gruis NA; Neuhausen S; Le Paslier D; Stockert E; Skolnick MH; Kamb A
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7563-7. PubMed ID: 8052620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines.
    Pollock PM; Walker GJ; Glendening JM; Que Noy T; Bloch NC; Fountain JW; Hayward NK
    Melanoma Res; 2002 Dec; 12(6):565-75. PubMed ID: 12459646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
    Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
    Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.
    Valsesia A; Rimoldi D; Martinet D; Ibberson M; Benaglio P; Quadroni M; Waridel P; Gaillard M; Pidoux M; Rapin B; Rivolta C; Xenarios I; Simpson AJ; Antonarakis SE; Beckmann JS; Jongeneel CV; Iseli C; Stevenson BJ
    PLoS One; 2011 Apr; 6(4):e18369. PubMed ID: 21494657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.